Glucocorticoids in the prevention of in-stent restenosis: The role of inflammation

International Journal of Cardiology

Volumn 135, Issue 3, 2009, Pages 403-405

  Celik, Turgay ^a   Iyisoy, Atila ^a   Barindik, Nadir ^b   Isik, Ersoy ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b TDV 29 Mayis Hospital   (Turkey)

Author keywords

Coronary stenting; Glucocorticoids; Inflammation; Restenosis

Indexed keywords

C REACTIVE PROTEIN; DEXAMETHASONE; GLUCOCORTICOID; GLUCOSE; LIPID; PACLITAXEL; PREDNISONE; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ARTERY INTIMA PROLIFERATION; ARTICLE; CORONARY STENT; DRUG ELUTING STENT; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; LIPID METABOLISM; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT;

CORONARY RESTENOSIS; DRUG-ELUTING STENTS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION MEDIATORS;

EID: 67349176197     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.01.057     Document Type: Article

References (13)

1. van der Hoeven B.L., Pires N.M., Warda H.M., et al. Dexamethasone-eluting stents for the prevention of in-stent restenosis: evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients. Int J Cardiol 124 (2008) 166-177
2. Gaspardone A., and Versaci F. Coronary stenting and inflammation. Am J Cardiol 96 12A (2005) 65L-70L
3. Suzuki T., Kopia G., Hayashi A., et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104 (2001) 1188-1193
4. Gaspardone A., Citone C., Versaci F., et al. Effect of sirolimus eluting stents and desametazone covered stents on post-procedural serum levels of C-reactive protein [abstract]. Ital Heart J (2004) 85
5. Romano M.F., Avellino R., Petrella A., Bisogni R., Romano S., and Venuta S. Rapamycin inhibits doxorubicin-induced NF-kB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 10 (2004) 2829-2836
6. Pepine C.J., Hirshfeld J.W., Macdonald R.G., et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 81 (1990) 1753-1761
7. Stone G.W., Rutherford B.D., McConahay D.R., et al. A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Catheter Cardiovasc Diagn 18 (1989) 227-231
8. Walter D.H., Fichtlscherer S., Sellwig M., Auch-Schwelk W., Schächinger V., and Zeiher A.M. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37 (2001) 839-846
9. Versaci F., Gaspardone A., Tomai F., et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study). J Am Coll Cardiol 40 (2002) 1935-1942
10. Patti G., Pasceri V., Carminati P., D'Ambrosio A., Carcagnì A., and Di Sciascio G. Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 95 (2005) 502-505
11. Rosano G.M., Collins P., Gerbara O., et al. Effect of estradiol 17beta upon coronary artery vasoconstrictor response to methylergometrine maleate in female menopausal patients. Int J Cardiol 107 (2006) 254-259
12. Rosano G.M., Gebara O., Sheiban I., et al. Acute administration of 17beta-estradiol reduces endothelin-1 release during pacing-induced ischemia. Int J Cardiol 116 (2007) 34-39
13. Maffei S., Mercuri A., Zucchelli G.C., and Vassalle C. Estrogen therapy effects on different vasoactive factors in recent postmenopausal healthy women. Int J Cardiol 107 (2006) 194-199